AlenCiken

FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer

AMEX:IGC   IGC Pharma, Inc.
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients

IGC Announces FDA Removal of Clinical Hold for Multiple Ascending Dose Study of IGC-AD1, Targeting Patients Suffering from Alzheimer’s-related Dementia

(FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer’s disease.

After the completion of administrative tasks, the Company plans to begin enrolling patients suffering from Alzheimer’s-related dementia for a 12-subject safety Multiple Ascending Dose (MAD) Study. The Company believes that the FDA’s approval of the initiation of the Phase 1 trial is a significant next step in IGC’s efforts to develop a potential therapy for treating patients suffering from a devastating disease.

"We believe that this a first human trail of this sort,"

Currently, there is no cure for Alzheimer’s disease.

finance.yahoo.c...-210300208.html?guce_refer...

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。